CGEN Stock Overview
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Compugen Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.60 |
| 52 Week High | US$11.75 |
| 52 Week Low | US$2.08 |
| Beta | 2.68 |
| 1 Month Change | -14.99% |
| 3 Month Change | -14.80% |
| 1 Year Change | 230.43% |
| 3 Year Change | -69.62% |
| 5 Year Change | -38.86% |
| Change since IPO | -7.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| CGEN | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -0.4% | 3.4% | 0.2% |
| 1Y | 230.4% | 3.9% | 5.4% |
Return vs Industry: CGEN exceeded the IL Biotechs industry which returned 5% over the past year.
Return vs Market: CGEN exceeded the IL Market which returned 5.1% over the past year.
Price Volatility
| CGEN volatility | |
|---|---|
| CGEN Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.2% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: CGEN's share price has been volatile over the past 3 months.
Volatility Over Time: CGEN's weekly volatility has decreased from 24% to 10% over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 68 | Anat Cohen-Dayag | cgen.com |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
Compugen Ltd. Fundamentals Summary
| CGEN fundamental statistics | |
|---|---|
| Market cap | ₪661.38m |
| Earnings (TTM) | -₪69.62m |
| Revenue (TTM) | ₪124.21m |
5.8x
P/S Ratio-10.3x
P/E RatioIs CGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEN income statement (TTM) | |
|---|---|
| Revenue | US$33.46m |
| Cost of Revenue | US$2.00m |
| Gross Profit | US$31.46m |
| Other Expenses | US$50.21m |
| Earnings | -US$18.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 94.01% |
| Net Profit Margin | -56.05% |
| Debt/Equity Ratio | 0% |
How did CGEN perform over the long term?
See historical performance and comparison